Person: EKER, SALİH SAYGIN
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
EKER
First Name
SALİH SAYGIN
Name
5 results
Search Results
Now showing 1 - 5 of 5
Publication Relationship between antidepressant prescription rates and features of schizophrenic patients and its outcome in schizophrenia treatment(Türk Noropsikiyatri Derneği, 2015-03-01) Hancı, Nurcan; Eker, Özlem Çetin; Miraloğlu, Özlem; Uslu, Meral Argün; Özkaya, Güven; Eker, Salih Saygın; Hancı, Nurcan; Eker, Özlem Çetin; Miraloğlu, Özlem; Uslu, Meral Argün; ÖZKAYA, GÜVEN; EKER, SALİH SAYGIN; Uludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Anabilim Dalı.; 0000-0003-0297-846X; 0000-0002-4345-0517; A-4421-2016; Q-9477-2019; CTO-3128-2022; CNL-3453-2022; FNP-5202-2022; JTT-6561-2023Introduction: Comorbid depression in schizophrenia is associated with poor outcome, increased risk of relapse and a high rate of suicide. Identification of depressive symptoms and their appropriate treatment is crucial for depressed schizophrenic patients. The aim of this study is to investigate the rates of antidepressant prescription and their outcomes.Methods: The records of the schizophrenic outpatients, who were consulted at Psychosis Unit of Psychiatry Department between January 2007 and September 2012, were evaluated retrospectively. Enrolled schizophrenic patients' antidepressant medications were at their minimal effective doses and effective duration.Results: The present study demonstrates that 39 of the 101 patients during their follow-ups were prescribed antidepressants. The mean follow-up period was 6.3 (+/- 4.2) years; the mean age at onset was 22 (+/- 6.5) years; the mean duration of illness was 14.7 (+7.3) years and the mean number of psychotic exacerbation was 5 (+/- 3.7). The most prescribed antidepressants were; sertraline (36.9%), venlefaxine (23.8%) and essitalopram (20.2%). SSRI's were prescribed 57 (73.1%), where as SNRI's 21 times (26.9%). There was no significant difference between SSRI (78.6%) and SNRI (21.4%) treatments in terms of psychotic exacerbation under antidepressant medication. Full remission of depressive symptoms was achieved in 21 patients (53.8%). Remission rates were significantly higher (p<0.01) in SNRI treated depressed schizophrenic patients (85.7%) compared to SSRI treated patients (50.9%). In 8 of the 39 patients (20.5%) antidepressant treatment was terminated due to side effects.Conclusion: This study demonstrates that SSRI's were more often prescribed compared to other classes of antidepressants in emerging depressive symptoms in schizophrenic patients despite full remission with SNRI's is more common. There was no significant difference between SSRI and SNRI treatment in terms of psychotic exacerbation.Publication The efficacy of flupenthixol decanoate in bipolar disorder patients who have no sufficient remission with existing treatments(Cumhuriyet Üniversitesi Tıp Fak Psikiyatri Anabilim Dalı, 2015-10-01) Eker, Salih Saygın; Akkaya, Cengiz; Pirinçci, Erdal; Cangür, Şengül; Kırlı, Selçuk; EKER, SALİH SAYGIN; AKKAYA, CENGİZ; Pirinçci, Erdal; KIRLI, SELÇUK; Uludağ Üniversitesi/Tıp Fakültesi/Ruh Sağlığı ve Hastalıkları Anabilim Dalı; Q-9477-2019; EKJ-8427-2022; FVU-0359-2022; CZU-1387-2022Objective: It is aimed to evaluate the prophylactic effect of flupenthixol decanoate in remitted BD patients. Methods: Remitted patients with bipolar disorder (BD), who had at least one mood episode each year in the last five years in spite of adequate pharmacotherapy, were included. Flupenthixol decanoate 20 mg/ml was administered in every two weeks. Hamilton Depression Rating Scale (HDRS), Young Mania Rating Scale (YMRS), Bipolar Disorder Functioning Questionnaire (BDFQ), General Assessment of Functionality (GAF) and Side Effect Rating Scale (UKU) were applied. Patients were followed up for 12 months. Results: Eight patients with a mean age of 34.7 +/- 7.5 were enrolled to the study. None of the patients were under monotherapy before the study enrollment. Three (37.5%) of the three patients were dropped out. The data of remaining 5 patients' were evaluated. At the end of the study mean number of mood episodes declined to 0.2 +/- 0.4 per year indicating a statistical significance and the mean score of BDFQ declined to 119.6 +/- 2.7. Conclusions: Flupenthixol decanoate significantly improved functionality and decreased the number of mood episodes allowing an alternative treatment even in remitted BD patients.Publication Successful ect treatment of a treatment resistant manic bipolar patient with intracra- nial mass and pulmonary embolism history: Case(Klinik Psikiyatri Dergisi, 2022-01-01) Muştucu, Anıl; Güllülü, Rümeysa Ayşe; Eker, Salih Saygın; MUŞTUCU, ANIL; GÜLLÜLÜ, RÜMEYSA AYŞE; EKER, SALİH SAYGIN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Anabilim Dalı.; INI-8383-2023; ILH-3122-2023; ICU-8104-2023Electroconvulsive therapy (ECT) is an effective and safe treatment method used in many psychiatric disorders. The efficacy and safety of ECT in the presence of an intracranial mass is controversial. The presence of a space-occupying mass was a contraindication to ECT until the 1980s. With the changes in ECT protocols over time and its application to more patients, positive data on the safety of ECT in intracranial masses have begun to accumulate. Available data suggest that ECT can be safe-ly used in patients with benign, small, and otherwise clinically insignificant tumors. A history of pulmonary embolism (PE) accompanying a psychiatric disorder may cause clinicians to avoid ECT. There are some concerns regarding the use of ECT in patients with a history of PE as there is little evidence for the safety of the implemen-tation of ECT. Although there is limited evidence regard-ing the safety of ECT in the presence of comorbidities, ECT can be successfully implemented where there is no response to other treatments with the necessary consul-tations and close follow-up, without delaying the treat-ment. In this article, a case who had been followed up with a bipolar affective disorder diagnosis, was hospita-lized for manic episode, who had comorbidities such as intracranial tumor and PE history, who did not benefit from psychotropic treatments and who responded sig-nificantly to nine sessions of ECT without any complica-tions is presented. The case presented here is, as far as is known, the first report where comorbidities such as intracranial tumor and pulmonary embolism history, which may cause clinicians to hesitate to implement ECT, co-exist.Publication Acute psychosis following covid-19 infection: A case report(Medicinska Naklada, 2022-01-01) Sarandöl, Aslı; SARANDÖL, ASLI; Güllülü, Rümeysa Ayşe; GÜLLÜLÜ, RÜMEYSA AYŞE; Eker, Salih Saygın; EKER, SALİH SAYGIN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Anabilim Dalı.Publication Comparison of effects of sertraline and reboxetine on the loss of social functioning in major depressive disorder: A randomized, open-labeled study(Kare Yayınevi, 2006-01-01) Akkaya, Cengiz; Sivrioğlu, E. Yusuf; Sarandöl, Aslı; Eker, S. Saygın; Kırlı, Selçuk; AKKAYA, CENGİZ; SİVRİOĞLU, ENVER YUSUF; SARANDÖL, ASLI; EKER, SALİH SAYGIN; KIRLI, SELÇUK; Uludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Anabilim Dalı.; Q-9477-2019; EKJ-8427-2022; GBQ-8020-2022; FTX-6743-2022; CZU-1387-2022Objective: In this study we aimed to compare the effects of sertraline and reboxetine, which are influential on two different neurotransmitters, on social functioning.Method: 41 patients conforming to the study protocol and who met DSM-IV MDD diagnostic criteria were recruited for the study. These subjects were distributed randomly into two groups, sertraline and reboxetine. The subjects were assessed six times during the study which lasted 11 weeks. At each assessment the subjects were asked to complete "Hamilton Depression Rating Scale" (HDRS), "Montgomery-Asberg Depression Rating Scale" (MADRS) and "Social Adaptation Self-evaluation Scale (SASS).Results: In both groups, the decrease in HDRS and MADRS scores was found to be statistically significant starting from the 2nd visit, compared to the values prior to medication. The decrease in SASS scores, on the other hand, was significant starting from the 3rd visit. In comparison of reboxetine and sertraline groups, HDRS scores were found to be significantly higher in the reboxetine group in visits 2, 3, and 4. However, no significant difference was found in MADRS and SASS scores.Discussion and Conclusion: In this study two antidepressants which create a selective effect via serotonin and noradrenalin were compared and it was found that clinically an earlier response and remission was provided with reboxetine. Nevertheless, it is notable that there was no statistically significant difference on their social functioning levels.